ZERO - THE END OF PROSTATE CANCER EDUCAT I ON NEWS L E T T E R
Winter 2021
In prostate cancer, many, many clinical trials are available. Oftentimes people do not participate in a clinical trial because they did not know they were eligible or that one is available. It is important to ask and learn about clinical trials when you are making a treatment decision since they may be an option for you. Below are a few prostate cancer clinical trials that you may be interested in. To learn about other available clinical trials, please visit our new clinical trial finder tool at www.zerocancer.org/find-a- clinical-trial . Phase 1 Study of TAS3681 Do you have metastatic castrate-resistant prostate cancer? A trial investigating safety & efficacy of a new treatment may be an option for you. Learn more: https://clinicaltrials.gov/ct2/ show/NCT02566772#studydesc Living with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)? Have you been diagnosed with metastatic castration-sensitive prostate cancer? Do you have a DNA Damage Repair (DDR) gene alteration? You may be eligible to take part in a clinical trial studying a potential treatment for this type of cancer. The TALAPRO-3 trial is evaluating whether talazoparib (the study drug) when taken with enzalutamide, an existing approved treatment for metastatic prostate cancer, can help keep tumors under control for longer than enzalutamide taken with placebo (an inactive medication). The trial will also explore the safety of this drug combination. Learn more: https://www.pfizerclinicaltrials.com/ nct04821622 Introducing P-PSMA-101: CAR-T for prostate cancer The P-PSMA-101-001 study is a Phase 1 clinical trial now enrolling patients at multiple locations in the United States. Conducted by Poseida Therapeutics, this study is testing P-PSMA-101, a new immunotherapy called a CAR-T. P-PSMA-101 is made from your own white blood cells that have been genetically modified in a lab to recognize a protein called PSMA. PSMA is commonly located on the surface of prostate cancer cells and P-PSMA-101 is designed to
kill the cancer cell. P-PSMA-101 is given via an intravenous infusion and you may be eligible to receive one or more infusions during the study. The purpose of this study is to determine if P-PSMA-101 is safe and will help treat patients with metastatic prostate cancer. You may be eligible for the study if you have progressing metastatic, castration resistant prostate cancer; and you have already been treated with a 2nd generation hormone therapy and a P-PSMA-101-001 study including hospitals enrolling patients visit the study registry at: clinicaltrials.gov/ct2/show/NCT04249947 Or contact Poseida at (858) 779-3103 or clinicaltrials@poseida.com https://poseida.com/patients/#clinicaltrials Veterans Update Prostate cancer is the most common cancer chemotherapy called a taxane. For more information about the diagnosis among American Veterans with one in five being diagnosed in their lifetime. With almost half a million Veterans currently being treated within the Veterans Health Administration (VHA), Veterans remain one of the most vulnerable groups. To help address these issues, ZERO is providing prostate cancer educational materials and support for Veterans, active duty military, and their physicians. We have a strong group of Veteran Champions who are willing and able to support policies that will improve the lives of their brothers in arms, and to share education and resources with those at risk. ZERO has convened the Veterans Prostate Cancer Working Group to help guide our policy efforts, including supporting the Veterans’ Prostate Cancer Treatment and Research Act, which was recently introduced both in the House (H.R. 4880) and Senate (S. 2720). ZERO recently also conducted the 2021 Veterans Prostate Cancer Survey, which gathered responses from over a thousand Veterans about their prostate cancer awareness and experience. The results of the survey will help inform our policies and programs. Check www.zerocancer.org/veterans to see the full analysis and learn more about ZERO’s efforts to help Veterans with prostate cancer.
6
Made with FlippingBook flipbook maker